References
1. Oldham R.A.A., Medin J.A. Practical considerations for chimeric antigen receptor design and delivery. Expert Opin. Biol. Ther. 2017; 17 (8): 961–78. DOI: https://doi.org/10.1080/14712598.2017.1339687
2. Sadelain M., Brentjens R., Riviere I. The basic principles of chimeric antigen receptor (CAR) design. Cancer Discov. 2013; 3 (4): 388–98. DOI: https://doi.org/10.1158/2159-8290.CD-12-0548
3. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., Maric I., Raffeld M., Nathan D.A., Lanier B.J., Morgan R.A., Rosenberg S.A. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116 (20): 4099–102. DOI: https://doi.org/10.1182/blood-2010-04-281931
4. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011; 365 (8): 725–33. DOI: https://doi.org/10.1056/NEJMoa1103849
5. Zhang L.N., Song Y., Liu D. CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. J. Hematol. Oncol. 2018; 11 (1): 41. DOI: https://doi.org/10.1186/s13045-018-0593-5
6. Zhang H., Ye Z.L., Yuan Z.G., Luo Z.Q., Jin H.J., Qian Q.J. New strategies for the treatment of solid tumors with CAR-T cells. Int. J. Biol. Sci. 2016; 12 (6): 718–29. DOI: https://doi.org/10.7150/ijbs.14405
7. Long A.H., Haso W.M., Shern J.F., Wanhainen K.M., Murgai M., Ingaramo M., Smith J.P., Walker A.J., Kohler M.E., Venkateshwara V.R., Kaplan R.N., Patterson G.H., Fry T.J., Orentas R.J., Mackall C.L. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 2015; 21 (6): 581–90. DOI: https://doi.org/10.1038/nm.3838
8. Kiselevsky M.V., Chikileva I.O., Sitdikova S.M., Vlasenko R.Ya., Karaulov A.V. Prospectives of application of the genetically modified lymphocytes with chimeric T-cell receptor (CAR-T-cells) for the therapy of solid tumors. Immunologiya. 2019; 40: 48–55. DOI: https://doi.org/10.24411/0206-4952-2019-14006 (in Russian)
9. Suzuki M., Cheung N.K. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin. Ther. Targets. 2015; 19 (3): 349–62. DOI: https://doi.org/10.1517/14728222.2014.986459
10. Nazha B., Inal C., Owonikoko T.K. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front. Oncol. 2020; 10: 1000. DOI: https://doi.org/10.3389/fonc.2020.01000
11. Keyel M.E., Reynolds C.P. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biol. Targets Ther. 2019; 13: 1–12. DOI: https://doi.org/10.2147/BTT.S114530
12. Savoldo B., Ramos C.A., Liu E., Mims M.P., Keating M.J., Carrum G., Kamble R.T., Bollard C.M., Gee A.P., Mei Z., Liu H., Grilley B., Rooney C.M., Heslop H.E., Brenner M.K., Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 2011; 121 (5): 1822–6. DOI: https://doi.org/10.1172/JCI46110
13. Ronchetti S., Nocentini G., Bianchini R., Krausz L.T., Migliorati G., Riccardi C. Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells. J. Immunol. 2007; 179 (9): 5916–26. DOI: https://doi.org/10.4049/jimmunol.179.9.5916
14. Ko K., Yamazaki S., Nakamura K., Nishioka T., Hirota K., Yamaguchi T., Shimizu J., Nomura T., Chiba T., Sakaguchi S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 2005; 202 (7): 885–91. DOI: https://doi.org/10.1084/jem.20050940
15. Golubovskaya V. M., Berahovich R., Xu Q., Zhou H., Xu S., Guan J., Harto H., Li L., Wu L. GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer. Front. Biosci. (Landmark ed.). 2018; 23 (12): 2245–54. DOI: https://doi.org/10.2741/4703
16. Ohmi Y., Kambe M., Ohkawa Y., Hamamura K., Tajima O., Takeuchi R., Furukawa K., Furukawa K. Differential roles of gangliosides in malignant properties of melanomas. PLoS One. 2018; 13 (11): e0206881. DOI: https://doi.org/10.1371/journal.pone.0206881
17. Golubovskaya V., Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers. 2016; 8 (3): 36. DOI: https://doi.org/10.3390/cancers8030036
18. Andersch L., Radke J., Klaus A., Schwiebert S., Winkler A., Schumann E., Grunewald L., Zirngibl F., Flemmig C., Jensen M.C., Rossig C., Joussen A., Henssen A., Eggert A., Schulte J.H., Künkele A. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer. 2019; 19 (1): 895. DOI: https://doi.org/10.1186/s12885-019-6131-1
19. Hudecek M., Lupo-Stanghellini M.T., Kosasih P.L., Sommermeyer D., Jensen M.C., Rader C., Riddell S.R. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 2013; 19 (12): 3153–64. DOI: https://doi.org/10.1158/1078-0432.CCR-13-0330
20. Zhao M., Fu L., Chai Y., Sun M., Li Y., Wang S., Qi J., Zeng B., Kang L., Gao G.F., Tan S. Atypical TNF-TNFR superfamily binding interface in the GITR-GITRL complex for T cell activation. Cell Rep. 2021; 36 (12): 109734. DOI: https://doi.org/10.1016/j.celrep.2021.109734
21. Yang R., Sun L., Li C.F., Wang Y.H., Yao J., Li H., Yan M., Chang W.C., Hsu J.M., Cha J.H., Hsu J.L., Chou C.W., Sun X., Deng Y., Chou C.K., Yu D., Hung M.C. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 2021; 12 (1): 832. DOI: https://doi.org/10.1038/s41467-021-21099-2
22. Bloemberg D., Nguyen T., MacLean S., Zafer A., Gadoury C., Gurnani K., Chattopadhyay A., Ash J., Lippens J., Harcus D., Pagé M., Fortin A., Pon R.A., Gilbert R., Marcil A., Weeratna R.D., McComb S. A high-throughput method for characterizing novel chimeric antigen receptors in Jurkat cells. Mol. Ther. Methods Clin. Dev. 2020; 16: 238–54. DOI: https://doi.org/10.1016/j.omtm.2020.01.012
23. Philipson B.I., O’Connor R.S., May M.J., June C.H., Albelda S.M., Milone M.C. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Sci. Signal. 2020; 13 (625): eaay8248. DOI: https://doi.org/10.1126/scisignal.aay8248
24. Kuhn N.F., Purdon T.J., van Leeuwen D.G., Lopez A.V., Curran K.J., Daniyan A.F., Brentjens R.J. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019; 35 (3): 473–88. DOI: https://doi.org/10.1016/j.ccell.2019.02.006
25. Malarkannan S. Molecular mechanisms of FasL-mediated «reverse-signaling». Mol. Immunol. 2020; 127: 31–37. DOI: https://doi.org/10.1016/j.molimm.2020.08.010
26. Benmebarek M.R., Karches C.H., Cadilha B.L., Lesch S., Endres S., Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci. 2019; 20 (6): 1283. DOI: https://doi.org/10.3390/ijms20061283